PURPOSE: In this report, the Pediatric Oncology Group (POG) experience with lymphocyte predominant Hodgkin Disease (LPHD) in children is reviewed. MATERIALS AND METHODS: From 1984-1993, the POG conducted 3 clinical trials for advanced stage HD and 2 for early stage HD. There were 26 cases of LPHD in 613 patients in these trials. Patients' ages ranged from 3.1-17.8 years (mean of 12.9 years). There was a marked male predominance. RESULTS: Histologic subtypes were 17 nodular, 8 diffuse pattern; 1 was indeterminant. The sites involved at diagnosis were primarily the peripheral lymph nodes. Fourteen patients had stage (S) I disease; 9 had SII; 3 had SIII; there was no SIV disease. Only 4 of 26 patients had B symptoms. All 26 patients achieved complete remission, 10 with radiotherapy, 6 with chemotherapy and 10 with combined modality therapy. Treatment was not uniform since patients were registered on different protocols. Event-free survival after 5 years was 86.5 percent. Two patients developed and succumbed to large cell, T-cell type, non-Hodgkin lymphoma (NHL). CONCLUSIONS: Optimal treatment for LPHD should focus on efforts to limit the risk of second malignancy.
PURPOSE: In this report, the Pediatric Oncology Group (POG) experience with lymphocyte predominant Hodgkin Disease (LPHD) in children is reviewed. MATERIALS AND METHODS: From 1984-1993, the POG conducted 3 clinical trials for advanced stage HD and 2 for early stage HD. There were 26 cases of LPHD in 613 patients in these trials. Patients' ages ranged from 3.1-17.8 years (mean of 12.9 years). There was a marked male predominance. RESULTS: Histologic subtypes were 17 nodular, 8 diffuse pattern; 1 was indeterminant. The sites involved at diagnosis were primarily the peripheral lymph nodes. Fourteen patients had stage (S) I disease; 9 had SII; 3 had SIII; there was no SIV disease. Only 4 of 26 patients had B symptoms. All 26 patients achieved complete remission, 10 with radiotherapy, 6 with chemotherapy and 10 with combined modality therapy. Treatment was not uniform since patients were registered on different protocols. Event-free survival after 5 years was 86.5 percent. Two patients developed and succumbed to large cell, T-cell type, non-Hodgkin lymphoma (NHL). CONCLUSIONS: Optimal treatment for LPHD should focus on efforts to limit the risk of second malignancy.
Authors: Monika L Metzger; Howard J Weinstein; Melissa M Hudson; Amy L Billett; Eric C Larsen; Alison Friedmann; Scott C Howard; Sarah S Donaldson; Matthew J Krasin; Larry E Kun; Karen J Marcus; Torunn I Yock; Nancy Tarbell; Catherine A Billups; Jianrong Wu; Michael P Link Journal: JAMA Date: 2012-06-27 Impact factor: 56.272
Authors: Uriel Bohn-Sarmiento; José C Rivero-Vera; David Aguiar-Bujanda; Miguel A Cabrera Santana; José Aguiar-Morales Journal: Clin Transl Oncol Date: 2006-06 Impact factor: 3.405
Authors: Ramona Vesna Untanu; Jason Back; Burton Appel; Qinglin Pei; Lu Chen; Allen Buxton; David C Hodgson; Peter F Ehrlich; Louis S Constine; Cindy L Schwartz; Robert E Hutchison Journal: Pediatr Blood Cancer Date: 2017-08-12 Impact factor: 3.167
Authors: Lianna J Marks; Qinglin Pei; Rizvan Bush; Allen Buxton; Burton Appel; Kara M Kelly; Cindy L Schwartz; Debra L Friedman Journal: Pediatr Blood Cancer Date: 2018-09-14 Impact factor: 3.167
Authors: Burton E Appel; Lu Chen; Allen Buxton; Suzanne L Wolden; David C Hodgson; James B Nachman Journal: Pediatr Blood Cancer Date: 2012-07-27 Impact factor: 3.167
Authors: Burton E Appel; Lu Chen; Allen B Buxton; Robert E Hutchison; David C Hodgson; Peter F Ehrlich; Louis S Constine; Cindy L Schwartz Journal: J Clin Oncol Date: 2016-05-16 Impact factor: 44.544